SteroTherapeutics LLC

SteroTherapeutics LLC is engaged in developing innovative drug therapies for orphan diseases, focusing primarily on Cushing's syndrome and Primary Sclerosing Cholangitis. The company aims to deliver effective treatments with fewer side effects than existing options. SteroTherapeutics LLC specializes in drug therapies targeting rare diseases. The company was founded to address significant unmet medical needs in niche markets and has its headquarters in the United States.

The firm has had one deal since its inception, with the most recent funding round occurring on February 27, 2018, where it raised an undisclosed amount from company management. SteroTherapeutics focuses on developing therapies for orphan diseases, particularly Cushing's syndrome and Primary Sclerosing Cholangitis (PSC). Their lead product, ST-002, is in partnership with the National Institutes of Health (NIH) to improve treatments for Cushing's syndrome. Additionally, ST-002 has potential applications in treating non-alcoholic steatohepatitis (NASH), while ST-003 targets PSC, a rare bile duct disorder.

The company aims to serve healthcare providers in the U. S. market. SteroTherapeutics generates revenue through strategic partnerships and research agreements, particularly with NIH for ST-002's development.

The revenue model likely includes B2B transactions with healthcare organizations and may involve milestone payments and royalties from clinical trials and product approvals. SteroTherapeutics plans to utilize recent funding from its February 2018 round to support the continued development of ST-002 and ST-003 therapies. The company is focused on launching these innovative products and expanding its reach within the U. S.

healthcare market. Specific timelines for product launches are not disclosed, but the strategic use of funding is aimed at enhancing their research capabilities and establishing further partnerships.